Supplemental material
Modern Rheumatology
Volume 30, 2020 - Issue 3
Open access
1,293
Views
2
CrossRef citations to date
0
Altmetric
Rheumatoid Arthritis
Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study
Masaru KatoDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; View further author information
, Yuko KanekoDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; View further author information
, Yoshiya TanakaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; View further author information
, Masayuki InooDepartment of Internal Medicine, Utazu Hospital, Ehime, Japan; View further author information
, Hitomi Kobayashi-HaraokaDivision of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan; View further author information
, Koichi AmanoDepartment of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; View further author information
, Masayuki MiyataDepartment of Internal Medicine, Fukushima Red Cross Hospital, Fukushima, Japan; View further author information
, Yohko MurakawaDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, Japan; View further author information
, Hidekata YasuokaDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; View further author information
, Shintaro HirataDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan; View further author information
, Hayato NagasawaDepartment of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; View further author information
, Eiichi TanakaInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan; View further author information
, Nobuyuki MiyasakaGraduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan; View further author information
, Hisashi YamanakaInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan; View further author information
, Kazuhiko YamamotoDepartment of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; View further author information
, Isao YokotaDepartment of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, JapanView further author information
, Tatsuya AtsumiDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; Correspondence[email protected]
View further author information
& View further author information
Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; View further author information
show all
Pages 442-449
|
Received 14 Mar 2019, Accepted 26 Apr 2019, Published online: 07 Jun 2019
Related Research Data
High sensitive C-reactive protein and serum amyloid A are inversely related to serum bilirubin: effect-modification by metabolic syndrome
Source:
Springer Nature
Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts
Source:
Informa UK Limited
Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)
Source:
Public Library of Science (PLoS)
Serum amyloid A (SAA) induces pentraxin 3 (PTX3) production in rheumatoid synoviocytes
Source:
Informa UK Limited
Pretreatment Prediction of Individual Rheumatoid Arthritis Patients’ Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers
Source:
Public Library of Science (PLoS)
The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Source:
Elsevier BV
Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
Source:
Springer Nature
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes
Source:
Oxford University Press (OUP)
Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study
Source:
Wiley-Blackwell
Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice
Source:
Oxford University Press (OUP)
Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.
Source:
Academy of Managed Care Pharmacy
Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study
Source:
Springer Nature
Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker
Source:
Springer Nature
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Source:
Elsevier BV
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study
Source:
Oxford University Press (OUP)
Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis
Source:
Spandidos Publications
Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis
Source:
Elsevier BV
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.